Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
MRTX

Mirati Therapeutics

$38.12

0.76 (2.03%)

12:02
11/30/18
11/30
12:02
11/30/18
12:02
Initiation
Mirati Therapeutics initiated at B. Riley FBR »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRTX

Mirati Therapeutics

$37.36

-2.09 (-5.30%)

17:21
11/29/18
11/29
17:21
11/29/18
17:21
Hot Stocks
Mirati Therapeutics announces FDA clears IND application for MRTX849 »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
MRTX

Mirati Therapeutics

$41.99

0.05 (0.12%)

08:44
11/09/18
11/09
08:44
11/09/18
08:44
Hot Stocks
Mirati Therapeutics presents data from Phase 2 trial of mocetinostat combination »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

  • 12

    Nov

  • 27

    Nov

MRTX

Mirati Therapeutics

$41.99

0.05 (0.12%)

08:37
11/09/18
11/09
08:37
11/09/18
08:37
Hot Stocks
Mirati Therapeutics presents data from Phase 2 trial of sitravatinib/nivolumab »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

  • 12

    Nov

  • 27

    Nov

MRTX

Mirati Therapeutics

$41.99

0.05 (0.12%)

, BGNE

BeiGene

$126.53

3.03 (2.45%)

16:34
11/08/18
11/08
16:34
11/08/18
16:34
Hot Stocks
Mirati Therapeutics: First patient dosed in Phase 1b trial of sitravatinib »

Mirati Therapeutics…

MRTX

Mirati Therapeutics

$41.99

0.05 (0.12%)

BGNE

BeiGene

$126.53

3.03 (2.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 12

    Nov

  • 14

    Nov

  • 27

    Nov

  • 01

    Dec

  • 03

    Dec

MRTX

Mirati Therapeutics

$39.19

0.96 (2.51%)

08:23
11/07/18
11/07
08:23
11/07/18
08:23
Recommendations
Mirati Therapeutics analyst commentary at Oppenheimer »

Mirati Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 12

    Nov

  • 27

    Nov

MRTX

Mirati Therapeutics

$39.19

0.96 (2.51%)

16:57
11/06/18
11/06
16:57
11/06/18
16:57
Earnings
Mirati Therapeutics reports Q3 EPS (85c), consensus (87c) »

Cash, cash equivalents,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 12

    Nov

  • 27

    Nov

MRTX

Mirati Therapeutics

$37.98

0.98 (2.65%)

15:34
10/31/18
10/31
15:34
10/31/18
15:34
Options
Mirati Therapeutics options imply 12.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

MRTX

Mirati Therapeutics

$34.96

0.26 (0.75%)

09:03
10/30/18
10/30
09:03
10/30/18
09:03
Hot Stocks
Mirati Therapeutics submits IND to FDA for phase 1/2 trial of KRAS G12C »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

MRTX

Mirati Therapeutics

$34.70

0.94 (2.78%)

07:01
10/29/18
10/29
07:01
10/29/18
07:01
Upgrade
Mirati Therapeutics rating change at Guggenheim »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.